CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Toshifumi Hibi, Yuya Imai, Yoko Murata, Nobuko Matsushima, Richuan Zheng, Christopher Gasink
Intest Res. 2017;15(4):475-486.   Published online October 23, 2017
DOI: https://doi.org/10.5217/ir.2017.15.4.475

Excel Download

Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn's disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal Research. 2017;15(4):475   Crossref logo
Link1 Link2 Link3

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Intestinal Research. 2021;19(4):386-397   Crossref logo
Link1 Link2 Link3

DOP71 Efficacy, safety, and tolerability of ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: Results from, UniStar, a phase 1 study
Journal of Crohn's and Colitis. 2020;14(Supplement_1):S107-S108   Crossref logo
Link1 Link2

1164 EFFICACY, SAFETY, TOLERABILITY OF USTEKINUMAB IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM UNISTAR, A PHASE 1 STUDY
Gastroenterology. 2020;158(6):S-235-S-236   Crossref logo
Link1 Link2

Ustekinumab in Paediatric Patients with Moderately to Severely Active Crohn’s Disease: Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study
Journal of Crohn's and Colitis. 2021;15(11):1931-1942   Crossref logo
Link1 Link2 Link3

Population Pharmacokinetics and Exposure–Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease
Clinical Therapeutics. 2022;   Crossref logo
Link1 Link2

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i037-i041   Crossref logo
Link1 Link2

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Gastroenterology. 2022;162(7):S-602   Crossref logo
Link1 Link2

OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i028-i029   Crossref logo
Link1 Link2

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis
Journal of Crohn's and Colitis. 2022;16(Supplement_1):i090-i091   Crossref logo
Link1 Link2